Sean Hennessy, PharmD, PhD
423 Guardian Drive
803 Blockley Hall
Philadelphia, PA 19104-6021
Philadelphia College of Pharmacy and Science, 1989.
PharmD (Clinical Pharmacy)
Philadelphia College of Pharmacy and Science, 1990.
MSCE (Clinical Epidemiology)
University of Pennsylvania School of Medicine, 1996.
PhD (Epidemiology with Biostatistics minor)
University of Pennsylvania, 2002.
Description of Research ExpertiseSean Hennessy leads Penn's Center for Pharmacoepidemiology Research and Training (CPeRT), and conducts research in the field of pharmacoepidemiology, which is the study of the health effects of drugs and other medical products in populations. He and his colleagues identified a survival benefit of potassium supplementation in users of loop diuretics, and found that this survival benefit increases with hotter outdoor temperature. They also found that the survival benefits of statin drugs increases with hotter outdoor temperature. He and his colleagues study serious health consequences of drug-drug interactions involving high-risk drugs including anticoagulants, antidiabetes drugs, and antiplatelet agents. Their research has produced crucial knowledge about the cardiovascular safety of many widely-used drugs for mental health conditions in including ADHD, depression, and schizophrenia. They also evaluated an early approach to using health insurance data to improve prescribing, finding it ineffective despite its federal mandate. This contributed to the omission of a requirement for drug utilization review programs in Medicare Part D. He co-led a pair of studies that demonstrated the effectiveness and safety of the SA14-14-2 vaccine for Japanese encephalitis (JE), which subsequently led to the immunization of millions of children per year in populous countries including Cambodia, India, Malaysia, Nepal, Sri Lanka, and Thailand. Use of that vaccine has been credited with reducing the worldwide incidence of JE. He and his colleagues developed the trend-in-trend research design for studying the effects of rapidly increasing or declining exposures. He was the senior author of one of two citizen petitions to the US Food and Drug Administration that led to re-labeling of metformin, the best-proven therapy for type 2 diabetes, to permit its use in persons with mild to moderate renal insufficiency. He is an elected member of the US National Academy of Medicine.
Description of Other ExpertiseDr. Hennessy is a past scientific chair and past president of the International Society for Pharmacoepidemiology, and has served on FDA’s Drug Safety and Risk Management Advisory Committee and on the board of directors of the American Society for Clinical Pharmacology and Therapeutics. He is a co-editor of the books Pharmacoepidemiology, 5th edition and Textbook of Pharmacoepidemiology, 2nd edition.
Director, Center for Pharmacoepidemiology Research & Training
Senior Scholar, Center for Clinical Epidemiology and Biostatistics
Senior Fellow, Leonard Davis Institute of Health Economics
Fellow, Institute on Aging
Co-Chair, Drug Use and Effects Committee, Hospital of the University of Pennsylvania
Member, Pharmacy Council, University of Pennsylvania Health System
Special Government Employee, US FDA
Member, Health Services and Organizational Delivery Study Section, US NIH
Member, Council for International Organizations of Medical Sciences (CIOMS) Work Group XIII on Real-World Data & Evidence in Regulatory Decision Making
EPI 666: Pharmacoepidemiology Research Methods
1998 Stanley A. Edlavitch Award for Best Abstract Submitted by a Student, International Society for Pharmacoepidemiology
2002 Saul Winegrad Award for Outstanding Dissertation in Epidemiology and Biostatistics, University of Pennsylvania
2005 Young Alumnus Award, University of the Sciences in Philadelphia
2008 Leon I Goldberg Young Investigator Award, American Society for Clinical Pharmacology & Therapeutics
2013 Samuel Martin Health Evaluation Sciences Research Award, University of Pennsylvania Perelman School of Medicine
2014 Julius W. Sturmer Memorial Lecture Award, Alpha Tau Chapter of the Rho Chi Society, Philadelphia College of Pharmacy, University of the Sciences
2015 Elected Member, National Academy of Medicine
Selected PublicationsNeuman MD, Hennessy S, Small DS, Newcomb C, Gaskins L, Brensinger CM, Wijeysundera DN, Bateman BT, Wunsch, H: Drug Enforcement Agency 2014 hydrocodone rescheduling rule and opioid dispensing after surgery. Anesthesiology 2020 DOI:10.1097/ALN.0000000000003188.
Miano T, Yang W, Shashaty M, Zuppa A, Brown J, Hennessy S: The magnitude of the warfarin-amiodarone drug-drug interaction varies with renal function: a propensity-matched cohort study. Clinical Pharmacology and Therapeutics 2020 (https://doi.org/10.1002/cpt.1819).
Zhou M, Leonard CE, Brensinger CM, Bilker WB, Kimmel SE, Hecht TE, Hennessy S.: Pharmacoepidemiologic screening of potential oral anticoagulant drug interactions leading to thromboembolic events. Clinical Pharmacology and Therapeutics 2020 (forthcoming).
Leonard CE, Brensinger CM, Dawwas GK, Deo R, Bilker WB, Soprano SE, Dhopeshwarkar N, Flory JH, Bloomgarden ZT, Gagne JJ, Aquilante CL, Kimmel SE, Hennessy S: The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety. Cardiovascular Diabetology 19: 25, 2020.
Zhou M, Leonard CE, Bilker WB, Hennessy S: The self-controlled case series design as a viable alternative to studying clinically relevant drug interactions [research letter]. Clinical Pharmacology and Therapeutics 107: 321-22, 2020.
Leonard CE, Zhou M, Brensinger CM, Bilker WB. Soprano SE, Pham Nguyen TP, Nam Y, Cohen JB, Hennessy S: Clopidogrel drug interactions and serious bleeding: High-throughput screening using the self-controlled case series design. Clinical Pharmacology and Therapeutics 2019 (doi:10.1002/cpt.1507).
Flory JH, Hennessy S, Bailey CJ, Inzucchi SE: Reports of Lactic Acidosis Attributed to Metformin, 2015-2018. Diabetes Care 2019 (doi: 10.2337/dc19-0923).
Gaulton TG, Wunsch H, Gaskins LJ, Leonard CE, Hennessy S, Ashburn M, Brensinger C, Newcomb C, Duminda W, Bateman BT, Bethell J, Neuman MD: Preoperative sedative-hypnotic medication use and adverse postoperative outcomes. Annals of Surgery 2019 (doi: 10.1097/SLA.0000000000003556).
Saine ME, Carbonari DM, Newcomb CW, Gallagher AM, Blak BT, Roy JA, Wood J, Cardillo S, Hennessy S, Strom BL, Lo Re V: Concordance of hospitalizations between Clinical Practice Research Datalink and linked Hospital Episode Statistics among patients treated with oral antidiabetic therapies. Pharmacoepidemiology and Drug Safety 2019 (doi: 10.1002/pds.4853).
Wehner MR, Kwong PL, Jurichi JE, Xie D, Hennessy S, Margolis DJ: Patient-reported health not associated with keratinocyte carcinoma treatment choice in a Medicare cohort of older adults [research letter] British Journal of Dermatology 2019 (DOI: 10.1111/bjd.18543).